Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
- Supplementary File 1:
ZIP-Document (ZIP, 2331 KiB)
Bouchalova, P.; Beranek, J.; Lapcik, P.; Potesil, D.; Podhorec, J.; Poprach, A.; Bouchal, P. Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment. Biomedicines 2021, 9, 1145. https://doi.org/10.3390/biomedicines9091145
Bouchalova P, Beranek J, Lapcik P, Potesil D, Podhorec J, Poprach A, Bouchal P. Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment. Biomedicines. 2021; 9(9):1145. https://doi.org/10.3390/biomedicines9091145
Chicago/Turabian StyleBouchalova, Pavla, Jindrich Beranek, Petr Lapcik, David Potesil, Jan Podhorec, Alexandr Poprach, and Pavel Bouchal. 2021. "Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment" Biomedicines 9, no. 9: 1145. https://doi.org/10.3390/biomedicines9091145